Education
About Us
Working with TipRanks
Follow Us
Assembly Biosciences (ASMB)
NASDAQ:ASMB
Total Valuation
Assembly Biosciences has a market cap or net worth of $489.05M. The enterprise value is $66.63M.
Market Cap$489.05M
Enterprise Value$66.63M
Share Statistics
Assembly Biosciences has 15,560,009 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding15,560,009
Owned by Insiders33.94%
Owned by Institutions60.21%
Financial Efficiency
Assembly Biosciences’s return on equity (ROE) is -1.20 and return on invested capital (ROIC) is -63.76%.
Return on Equity (ROE)-1.20
Return on Assets (ROA)-0.34
Return on Invested Capital (ROIC)-63.76%
Return on Capital Employed (ROCE)-0.64
Revenue Per Employee390.68K
Profits Per Employee-550.37K
Employee Count73
Asset Turnover0.24
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Assembly Biosciences is ―. Assembly Biosciences’s PEG ratio is 0.05.
PE Ratio―
PS Ratio3.32
PB Ratio2.84
Price to Fair Value2.84
Price to FCF-1.85
Price to Operating Cash Flow-4.98
PEG Ratio0.05
Income Statement
In the last 12 months, Assembly Biosciences had revenue of 28.52M and earned -40.18M in profits. Earnings per share was -6.69.
Revenue28.52M
Gross Profit28.52M
Operating Income-45.42M
Pretax Income-39.85M
Net Income-40.18M
EBITDA-45.29M
Earnings Per Share (EPS)-6.69
Cash Flow
In the last 12 months, operating cash flow was -55.74M and capital expenditures -42.00K, giving a free cash flow of -55.78M billion.
Operating Cash Flow-55.74M
Free Cash Flow-55.78M
Free Cash Flow per Share-3.58
Dividends & Yields
Assembly Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.38
52-Week Price Change106.65%
50-Day Moving Average30.31
200-Day Moving Average19.60
Relative Strength Index (RSI)49.65
Average Volume (3m)164.41K
Important Dates
Assembly Biosciences upcoming earnings date is Mar 5, 2026, After Close (Confirmed).
Last Earnings DateNov 10, 2025
Next Earnings DateMar 5, 2026
Ex-Dividend Date―
Financial Position
Assembly Biosciences as a current ratio of 2.42, with Debt / Equity ratio of 15.93%
Current Ratio2.42
Quick Ratio2.42
Debt to Market Cap0.00
Net Debt to EBITDA0.78
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Assembly Biosciences has paid 330.00K in taxes.
Income Tax330.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Assembly Biosciences EV to EBITDA ratio is -1.31, with an EV/FCF ratio of -1.16.
EV to Sales2.09
EV to EBITDA-1.31
EV to Free Cash Flow-1.16
EV to Operating Cash Flow-1.16
Balance Sheet
Assembly Biosciences has $232.56M in cash and marketable securities with $2.75M in debt, giving a net cash position of $229.80M billion.
Cash & Marketable Securities$232.56M
Total Debt$2.75M
Net Cash$229.80M
Net Cash Per Share$14.77
Tangible Book Value Per Share$5.56
Margins
Gross margin is 99.86%, with operating margin of -159.26%, and net profit margin of -140.87%.
Gross Margin99.86%
Operating Margin-159.26%
Pretax Margin-139.72%
Net Profit Margin-140.87%
EBITDA Margin-159.26%
EBIT Margin-159.26%
Analyst Forecast
The average price target for Assembly Biosciences is $41.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$41.75
Price Target Upside23.19% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast31.30%
EPS Growth Forecast32.79%